MCID: BCT013
MIFTS: 49

Bacterial Pneumonia

Categories: Infectious diseases, Respiratory diseases

Aliases & Classifications for Bacterial Pneumonia

MalaCards integrated aliases for Bacterial Pneumonia:

Name: Bacterial Pneumonia 12 75 15 17
Pneumonia Due to Other Gram-Negative Bacteria 12
Gram-Negative Pneumonia 12
Pneumonia, Bacterial 44
Pneumonia Bacterial 55

Classifications:



External Ids:

Disease Ontology 12 DOID:874
ICD9CM 35 482.9
MeSH 44 D018410
NCIt 50 C26704
SNOMED-CT 68 53084003
ICD10 33 J15 J15.9
UMLS 72 C0004626

Summaries for Bacterial Pneumonia

Disease Ontology : 12 A pneumonia involving inflammation of the lungs caused by bacteria.

MalaCards based summary : Bacterial Pneumonia, also known as pneumonia due to other gram-negative bacteria, is related to mycoplasma pneumoniae pneumonia and adult respiratory distress syndrome. An important gene associated with Bacterial Pneumonia is CRP (C-Reactive Protein), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Tobramycin and Vancomycin have been mentioned in the context of this disorder. Affiliated tissues include lung, neutrophil and testes, and related phenotype is respiratory system.

Wikipedia : 75 Bacterial pneumonia is a type of pneumonia caused by bacterial... more...

Related Diseases for Bacterial Pneumonia

Diseases in the Pneumonia family:

Viral Pneumonia Bacterial Pneumonia

Diseases related to Bacterial Pneumonia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 306)
# Related Disease Score Top Affiliating Genes
1 mycoplasma pneumoniae pneumonia 32.5 IL6 IL17A CRP
2 adult respiratory distress syndrome 30.5 SFTPB IL6 ELANE CXCL8
3 pyomyositis 30.4 GPT CRP
4 viral pneumonia 30.4 IL6 IL17A CRP
5 chlamydia 30.4 TLR4 IL6 CXCL8 CRP
6 toxic shock syndrome 30.4 TLR4 IL6 CXCL8
7 bacterial meningitis 30.3 IL6 CXCL8 CRP
8 acute respiratory distress syndrome 30.2 SFTPD SFTPB IL6 ELANE CXCL8
9 idiopathic interstitial pneumonia 30.2 SFTPD ELANE CXCL8
10 bronchitis 30.1 LACTB ELANE CXCL8 CRP
11 endocarditis 30.1 LACTB IL6 CXCL8 CRP
12 respiratory syncytial virus infectious disease 30.1 SFTPB CCL3
13 peritonitis 30.0 IL6 CXCL8 CRP ADA
14 gastritis 30.0 DEFB4A CXCL8 CXCL1
15 avian influenza 29.9 SFTPD IL6 CXCL8
16 deficiency anemia 29.9 IL6 CSF3 CRP
17 pericardial effusion 29.9 IL6 CRP ADA
18 pericarditis 29.9 IL6 CRP ADA
19 acute cystitis 29.8 IL6 CXCL8 CXCL1 CRP
20 aspergillosis 29.8 TLR4 SFTPD ELANE
21 silicosis 29.8 SFTPD SCGB1A1 CXCL8
22 invasive aspergillosis 29.7 TLR4 SFTPD CXCL8
23 cerebrovascular disease 29.6 TLR4 IL6 CRP
24 respiratory failure 29.6 SFTPD SFTPB SCGB1A1 ELANE CXCL8 CRP
25 bacterial sepsis 29.6 TLR4 ELANE CXCL8 CRP
26 interstitial lung disease 29.6 SFTPD SFTPB IL6 CXCL8
27 otitis media 29.3 TLR4 LACTB IL6 CXCL8
28 human immunodeficiency virus type 1 29.3 IL6 CXCL1 CCL3 ADA
29 kaposi sarcoma 29.2 IL6 CXCL8 CXCL1
30 skin disease 29.0 IL22 IL17A DEFB4A CXCL8
31 newborn respiratory distress syndrome 28.8 SFTPD SFTPB SCGB1A1 IL6 ELANE CXCL8
32 pneumonia 28.8 TLR4 SFTPD SFTPB LACTB IL6 ELANE
33 cystic fibrosis 28.8 TLR4 SFTPD ELANE DEFB4A CXCL8
34 bacterial infectious disease 28.5 TLR4 IL6 IL17A ELANE DEFB4A CXCL8
35 mycobacterium tuberculosis 1 28.4 TLR4 IL17A ADA
36 lung disease 28.4 SFTPD SFTPB IL6 IL17A ELANE CXCL8
37 meningitis 28.3 LACTB IL6 CXCL8 CXCL1 CRP CCL3
38 pulmonary disease, chronic obstructive 28.0 SFTPD SFTPB SCGB1A1 IL6 IL17A ELANE
39 pulmonary fibrosis, idiopathic 28.0 SFTPD SFTPB SCGB1A1 ELANE CXCL8 CXCL1
40 bronchiolitis 27.8 TLR4 IL6 IL17A CXCL8 CRP CCL3
41 asthma 27.6 SCGB1A1 IL6 IL17A ELANE CXCL8 CXCL1
42 proteasome-associated autoinflammatory syndrome 1 27.4 TLR4 IL6 IL17A ELANE CXCL8 CRP
43 klebsiella pneumonia 11.7
44 influenza 11.5
45 chlamydia pneumonia 11.5
46 aspiration pneumonia 11.5
47 pleural empyema 11.5
48 streptococcus pneumonia 11.5
49 myasthenic syndrome, congenital, 1a, slow-channel 10.7 CXCL8 CRP
50 cold agglutinin disease 10.7 IL6 CRP

Graphical network of the top 20 diseases related to Bacterial Pneumonia:



Diseases related to Bacterial Pneumonia

Symptoms & Phenotypes for Bacterial Pneumonia

MGI Mouse Phenotypes related to Bacterial Pneumonia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 respiratory system MP:0005388 9.17 ADA IL17A IL6 SCGB1A1 SFTPB SFTPD

Drugs & Therapeutics for Bacterial Pneumonia

Drugs for Bacterial Pneumonia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 206)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
2
Vancomycin Approved Phase 4 1404-90-6 441141 14969
3
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
4
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
5
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
6
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
7
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
9
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
10
Zidovudine Approved Phase 4 30516-87-1 35370
11
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
12
Nevirapine Approved Phase 4 129618-40-2 4463
13
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
14
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
15
Ofloxacin Approved Phase 4 82419-36-1 4583
16
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
17
Ribavirin Approved Phase 4 36791-04-5 37542
18
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
19
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
20 HIV Protease Inhibitors Phase 4
21
protease inhibitors Phase 4
22 Micronutrients Phase 4
23 Hormones Phase 4
24 Trace Elements Phase 4
25 Nutrients Phase 4
26 Amoxicillin-Potassium Clavulanate Combination Phase 4
27 Gastrointestinal Agents Phase 4
28 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
29 Vaccines Phase 4
30 Immunologic Factors Phase 4
31 Anti-Inflammatory Agents Phase 4
32 Peripheral Nervous System Agents Phase 4
33 Autonomic Agents Phase 4
34 Antiemetics Phase 4
35 glucocorticoids Phase 4
36 Antineoplastic Agents, Hormonal Phase 4
37 Hormone Antagonists Phase 4
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
39 Clindamycin palmitate Phase 4
40 Clindamycin phosphate Phase 4
41 MF59 oil emulsion Phase 4
42 BB 1101 Phase 4
43 Anti-Retroviral Agents Phase 4
44 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
45 Liver Extracts Phase 4
46 Renal Agents Phase 4
47 Anti-Infective Agents, Urinary Phase 4
48 Topoisomerase Inhibitors Phase 4
49 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
50 Lactams Phase 4

Interventional clinical trials:

(show top 50) (show all 195)
# Name Status NCT ID Phase Drugs
1 Individualizing Duration of Antibiotic Therapy in Hospitalized Patients With Community - Acquired Pneumonia: a Non-inferiority, Randomized, Controlled Trial. Unknown status NCT01492387 Phase 4
2 Ventilator Associated Pneumonia: Addition of Tobramycin Inhalation Antibiotic Treatment to Standard IV Antibiotic Treatment Unknown status NCT02440828 Phase 4 tobramycin inhalation;placebo
3 Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia (CABP) Completed NCT01524302 Phase 4 Ceftaroline;Levofloxacin
4 A Multicenter, Multinational, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil Versus Ceftriaxone Plus Vancomycin in Adult Subjects With Community-acquired Bacterial Pneumonia at Risk for Infection Due to Methicillin-resistant Staphylococcus Aureus Completed NCT01645735 Phase 4 Ceftaroline fosamil;Ceftriaxone plus vancomycin
5 Title: Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia During the Influenza Season (U18) Completed NCT01248715 Phase 4 oseltamivir
6 Phase 4 Randomized Multicentric Controlled Study on Impact of Continuous Venovenous Hemofiltration on Organ Failure at the Early Phase of Severe Sepsis Completed NCT00406198 Phase 4
7 A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone Plus Vancomycin in Pediatric Subjects With Complicated Community-acquired Bacterial Pneumonia (CABP) Completed NCT01669980 Phase 4 Ceftaroline fosamil;IV Ceftriaxone and Vancomycin
8 Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy Completed NCT00402805 Phase 4
9 A Randomized Controlled Trial Comparing Adjuvanted vs. Nonadjuvanted Influenza Vaccine in Adult Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients. Completed NCT02560909 Phase 4
10 A Comparative, Randomised Controlled Trial for Evaluating the Efficacy of Dexamethasone in the Treatment of Patients With Acute Respiratory Distress Syndrome Completed NCT01731795 Phase 4 Dexamethasone
11 Randomized, Controlled Clinical Trial of Day-care Based and Hospitalized Management of Severe and Very Severe Pneumonia, With Severe Malnutrition, With/Without Associated Co-morbidities in Children Completed NCT00968370 Phase 4
12 A Randomised Controlled Trial Comparing Two-Dose Priming With the 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks to 6 and 14 Weeks in Nepali Children Completed NCT02385513 Phase 4
13 Evaluation of World Health Organization (WHO) Recommendations on Test and Treat Strategy, Managing Advanced HIV Disease and Rapid Initiation of ART Among People Living With HIV in Nepal: A Cluster Randomized Trial. Active, not recruiting NCT03723525 Phase 4
14 Comparison Between Ceftriaxone and Levofloxacin on Cytokine Expression Over Time in Severe Pneumococcal Pneumonia Terminated NCT00429975 Phase 4 levofloxacin;ceftriaxone
15 Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon Terminated NCT00687544 Phase 4 Ribavirin (SCH 018908)
16 A Multicenter Study to Describe the Safety and Efficacy of Ceftaroline Fosamil in Elderly Subjects With Community-Acquired Bacterial Pneumonia Withdrawn NCT01666743 Phase 4 Ceftaroline fosamil
17 Randomized Aseptic Pharmacokinetic Pharmacodynamic Outpatient Registry Trial of Respiratory Tract Infections in Adults (RAPPORT) Withdrawn NCT00245453 Phase 4 azithromycin;telithromycin;Clarythromycin
18 A Phase III Study to Evaluate the Efficacy and Safety of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia Unknown status NCT01937832 Phase 3 Faropenem;Ertapenem
19 The Effect of Ulinastatin on Bronchoalveolar Lavage Fluid of Inflammatory Factors in Patients With Ventilator-associated Pneumonia Unknown status NCT01865266 Phase 2, Phase 3 Ulinaststin for injection;placebo
20 Phase 3b Randomized Double Blind Controled Placebo Comparative Trial of Intravenous Colistin vs Intravenous Colistin Plus Nebulized Colistin in Patients With Ventilator-associated Pneumonia (VAP) Due Multiresistant Acinetobacter Baumanii Unknown status NCT00645723 Phase 3 Colistin;Colistin and saline solution
21 Randomized Controlled Trial of Intramuscular Ceftriaxone Versus Procaine Penicillin Versus Cotrimoxazole and Gentamicin for Management of Serious Bacterial Infections in Young Infants in Community Settings Unknown status NCT00189384 Phase 3 ceftriaxone, procaine penicillin and gentamicin, oral cotrimoxazole and gentamicin
22 Safety and Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine Among Solid Organ Transplant Recipients: Protocol 1A and 1B Unknown status NCT00213265 Phase 3
23 A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients With Gram-Negative Pneumonia Completed NCT01799993 Phase 3 Amikacin Inhalation Solution (BAY41-6551);Aerosolized Placebo
24 Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae Completed NCT00540072 Phase 3 daptomycin
25 A Randomized, Double-Blind, Phase III, Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae Completed NCT00538694 Phase 3 daptomycin
26 A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Intravenous Tigecycline Vs Intravenous Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia Completed NCT00081575 Phase 3 Tigecycline;Levofloxacin
27 A Multicenter, Unblinded, Non-Comparative Study Of Unasyn-S 12 G/Day Evaluating The Safety And Efficacy In Japanese Adult Subjects With Community Acquired Pneumonia Completed NCT01189487 Phase 3 ampicillin sodium/sulbactam sodium
28 A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia Completed NCT02531438 Phase 3 Omadacycline;Moxifloxacin
29 A Phase III, Multicentre, Randomised, Double-Blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia Completed NCT01371838 Phase 3 Ceftaroline;Ceftriaxone
30 A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Tigecycline Vs Imipenem/Cilastatin For The Treatment Of Subjects With Nosocomial Pneumonia Completed NCT00080496 Phase 3 Tigecycline;Imipenem;Cilastatin
31 A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Tigecycline Vs Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia Completed NCT00079885 Phase 3 tigecycline
32 A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus Aureus Completed NCT00124020 Phase 3 Telavancin;Vancomycin
33 A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus Aureus Completed NCT00107952 Phase 3 Telavancin;Vancomycin
34 Ceftaroline Fosamil Versus Standard of Care for Community Acquired Bacterial Pneumonia (CABP): Clinical Outcomes Among Hospitalized Adults at a Single United States Hospital Completed NCT01605864 Phase 3 Efficacy of ceftaroline
35 A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects With Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia Completed NCT02493764 Phase 3 Imipenem;Relebactam;Cilastatin;Piperacillin;Tazobactam;Linezolid
36 A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in the Treatment of Adult Patients With Community-Acquired Bacterial Pneumonia Completed NCT01968733 Phase 3 Solithromycin;Moxifloxacin
37 A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in the Treatment of Adult Patients With Community-Acquired Bacterial Pneumonia Completed NCT01756339 Phase 3 Solithromycin;Moxifloxacin
38 A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC 3781) Versus Oral Moxifloxacin in Adults With Community-Acquired Bacterial Pneumonia Completed NCT02813694 Phase 3 lefamulin;Moxifloxacin
39 A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone in Pediatric Subjects With Community-acquired Bacterial Pneumonia Requiring Hospitalization Completed NCT01530763 Phase 2, Phase 3 Ceftaroline fosamil;Ceftriaxone;amoxicillin clavulanate
40 A Phase 3, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety and Efficacy of Intravenous to Oral Delafloxacin in Adult Subjects With Community-Acquired Bacterial Pneumonia Completed NCT02679573 Phase 3 Delafloxacin;Moxifloxacin;Linezolid
41 A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community-Acquired Bacterial Pneumonia Completed NCT02559310 Phase 3 lefamulin;Moxifloxacin;Linezolid
42 A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE) Completed NCT01970371 Phase 3 plazomicin;colistin;meropenem;tigecycline;antibiotic of Investigator's choice
43 Randomized, Open Label, Multicenter, Non-inferiority Trial to Compare Safety and Efficacy of Colistin vs. Meropenem in VAP Caused by CR-GNB Completed NCT01292031 Phase 3 Colistin;Meropenem
44 A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone in the Treatment of Adult Subjects With Community-Acquired Pneumonia Completed NCT00509106 Phase 3 Ceftaroline fosamil for Injection;Ceftriaxone;Placebo
45 A Prospective, Non-randomized, Open-label, Non-controlled, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics/ Pharmacodynamics of BAYQ3939 (400 mg BID and TID) in Hospitalized Patients With Bacterial Pneumonia or Secondary Infection of Chronic Respiratory Disease With Severe Disease or a Poor Response to Other Antimicrobials Completed NCT01561794 Phase 3 Ciprofloxacin (Cipro, BAYQ3939)
46 A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Ceftriaxone, With Adjunctive Clarithromycin, in the Treatment of Adult Subjects With Community-Acquired Pneumonia Completed NCT00621504 Phase 3 Ceftaroline fosamil for Injection;IV Ceftriaxone;Placebo;Clarithromycin
47 Acute Respiratory Infections and Asthma in U-5 Children: Improved Treatment to Reduce Morbidity and Mortality in Uganda, A Randomized Controlled Trial Completed NCT01868113 Phase 3 Inhaled corticosteroid
48 Parapneumonic Effusion in Children Study Completed NCT00202826 Phase 3
49 An International, Multicenter, Randomized, Double-blind, Double-dummy, Two-way, Parallel Group, Controlled Study to Compare the Efficacy and Safety of Intravenous and Oral Nemonoxacin Versus Tavanic® in Adult Patients With Community-acquired Pneumonia Completed NCT03551210 Phase 3 Nemonoxacin;Nemonoxacin;Tavanic;Tavanic;Placebo (250 ml);Placebo (100 ml)
50 A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE) Completed NCT02168946 Phase 3 Vabomere;Best Available Therapy

Search NIH Clinical Center for Bacterial Pneumonia

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Cefotaxime
Clindamycin

Cochrane evidence based reviews: pneumonia, bacterial

Genetic Tests for Bacterial Pneumonia

Anatomical Context for Bacterial Pneumonia

MalaCards organs/tissues related to Bacterial Pneumonia:

41
Lung, Neutrophil, Testes, Skin, Colon, Bone, Liver

Publications for Bacterial Pneumonia

Articles related to Bacterial Pneumonia:

(show top 50) (show all 3452)
# Title Authors PMID Year
1
Myeloperoxidase-dependent inactivation of surfactant protein D in vitro and in vivo. 9 38
20228064 2010
2
Prognostic value of C-reactive protein in HIV-infected patients with Pneumocystis jirovecii pneumonia. 9 38
20378904 2010
3
2009 influenza A (H1N1): a clinical review. 9 38
20469616 2010
4
MyD88-dependent TLR4 signaling is selectively impaired in alveolar macrophages from asymptomatic HIV+ persons. 9 38
20197549 2010
5
Is procalcitonin better than C-reactive protein for early diagnosis of bacterial pneumonia in children? 9 38
20087955 2010
6
Validity of the quick-read C-reactive protein test in the prediction of bacterial pneumonia in the pediatric emergency department. 9 38
18460957 2008
7
The utility of serum C-reactive protein in differentiating bacterial from nonbacterial pneumonia in children: a meta-analysis of 1230 children. 9 38
18174874 2008
8
Evaluation of serum amyloid A and surfactant protein D in sera for identification of the clinical condition of horses with bacterial pneumonia. 9 38
17827889 2007
9
Procalcitonin versus C-reactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care. 9 38
17727748 2007
10
[Changes and clinical significance of Toll-like receptor 2 and 4 expression in neonatal infections]. 9 38
17456342 2007
11
Disease severity in patients with simultaneous influenza and bacterial pneumonia. 9 38
17603232 2007
12
[Clinical features and outcome in 84 patients with influenza pneumonia]. 9 38
17087332 2006
13
Neutrophil serine proteinases inactivate surfactant protein D by cleaving within a conserved subregion of the carbohydrate recognition domain. 9 38
15078883 2004
14
C-reactive protein in the diagnosis of community-acquired pneumonia. 9 38
14533984 2003
15
Correlations between serum amyloid A protein and C-reactive protein in infectious diseases. 9 38
12940634 2003
16
Bacterial pneumonia can increase serum concentration of clozapine. 9 38
12185555 2002
17
Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. 9 38
11818324 2002
18
Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. 9 38
11588011 2001
19
Procalcitonin in children admitted to hospital with community acquired pneumonia. 9 38
11259234 2001
20
Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children. 9 38
10917215 2000
21
[A study of human beta-defensin-1 and human beta-defensin-2 in airway mucosal defense]. 9 38
10213993 1999
22
[Significance of serum surfactant protein-D (SP-D) level in patients with pulmonary tuberculosis]. 9 38
9844346 1998
23
Identification of human beta-defensin-2 in respiratory tract and plasma and its increase in bacterial pneumonia. 9 38
9731241 1998
24
Value of C-reactive protein in the detection of bacterial contamination at the time of presentation in drug-induced aspiration pneumonia. 9 38
9266885 1997
25
[Diagnostic value of serum soluble interleukin-2 receptor levels in interstitial pneumonia of the patients with hematological disorders]. 9 38
9059070 1997
26
Adenosine deaminase activity in the aetiological diagnosis of community-acquired pneumonia. 9 38
9255891 1997
27
[A comparative study of tazobactam/piperacillin and piperacillin in bacterial pneumonia]. 9 38
7783313 1995
28
[Diagnostic value of C-reactive protein in comparison with erythrocyte sedimentation as routine admission diagnostic test]. 9 38
7878400 1995
29
Possible low response of C-reactive protein production in eosinophilic pneumonia. 9 38
8735434 1995
30
Utility of C-reactive protein measurements for empyema diagnosis after pneumonectomy. 9 38
8166544 1994
31
The C-reactive protein responses in HIV-infected patients with pneumonia. 9 38
8362226 1993
32
[Studies on risk factors influencing delayed resolution of pneumonia]. 9 38
1294663 1992
33
Efficacy and safety of loracarbef in the treatment of pneumonia. 9 38
1621747 1992
34
[Pneumonia caused by Moraxella subgenus Moraxella sp]. 9 38
1624833 1992
35
Adenosine deaminase activity and free IL-2 receptor levels in serum from patients with mycoplasma pneumonia. 9 38
1907690 1991
36
Lung ultrasonography findings in dogs with various underlying causes of cough. 38
31429645 2019
37
Impact of additional antibiotics on in-hospital mortality in tuberculosis isolated general bacteria: A propensity score analysis. 38
30982726 2019
38
Influenza in Children With Special Risk Medical Conditions: A Systematic Review and Meta-analysis. 38
31274833 2019
39
Empyema necessitans in a six-month-old girl. 38
29790830 2019
40
Risk of bacterial pneumonia and pneumococcal infection in youths with celiac disease - A population-based study. 38
30926284 2019
41
The bacterial aetiology of pleural empyema. A descriptive and comparative metagenomic study. 38
30580031 2019
42
Treating bacterial pneumonia in people living with HIV. 38
31241378 2019
43
Critically Ill Patients with the HIV: 40 Years Later. 38
31421114 2019
44
Omadacycline: A Novel Tetracycline Derivative With Oral and Intravenous Formulations. 38
30893428 2019
45
Cytological Findings in Bronchoalveolar Lavage Fluid of Foals With Pneumonia Caused by Rhodococcus equi and Other Bacteria. 38
31405508 2019
46
Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Practice. 38
31367741 2019
47
Therapeutic Effects of Hyaluronic Acid in Bacterial Pneumonia in the Ex Vivo Perfused Human Lungs. 38
31390880 2019
48
A Japanese Case of Primary Ciliary Dyskinesia with DNAH5 Mutations. 38
31118369 2019
49
An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic. 38
31367740 2019
50
Population Pharmacokinetic Analyses for Arbekacin after Administration of ME1100 Inhalation Solution. 38
31182524 2019

Variations for Bacterial Pneumonia

Expression for Bacterial Pneumonia

Search GEO for disease gene expression data for Bacterial Pneumonia.

Pathways for Bacterial Pneumonia

Pathways related to Bacterial Pneumonia according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 TLR4 IL6 IL22 IL17A ELANE DEFB4A
2
Show member pathways
13.58 TLR4 IL6 IL22 IL17A CXCL8 CXCL1
3
Show member pathways
13.32 TLR4 IL6 IL22 IL17A CXCL8 CXCL1
4
Show member pathways
13.28 IL6 IL22 IL17A CXCL8 CXCL1 CSF3
5
Show member pathways
13.22 IL6 IL22 IL17A CXCL8 CXCL1 CSF3
6
Show member pathways
13.02 TLR4 SFTPD IL6 CXCL8 CXCL1 CCL3
7
Show member pathways
12.49 TLR4 IL6 IL22 IL17A
8
Show member pathways
12.18 IL6 IL17A DEFB4A CXCL8 CXCL1 CSF3
9
Show member pathways
12.16 CXCL8 CXCL1 CCL3
10
Show member pathways
12.09 TLR4 SFTPD IL6 DEFB4A CXCL8
11
Show member pathways
12.01 IL6 IL22 IL17A CXCL8 CCL3
12
Show member pathways
12.01 TLR4 IL6 IL22 IL17A
13 11.95 TLR4 IL6 CXCL8 CXCL1
14 11.88 IL6 IL17A CXCL8
15 11.87 IL6 CXCL8 CXCL1 CCL3
16 11.85 TLR4 IL6 CXCL8 CXCL1
17 11.71 IL22 IL17A CCL3
18 11.68 TLR4 IL6 CXCL8
19 11.66 IL6 IL17A CXCL1 CCL3
20 11.63 TLR4 IL6 CXCL8 CXCL1 CCL3
21 11.6 IL6 CXCL8 CSF3 CCL3
22
Show member pathways
11.6 TLR4 IL6 IL17A CXCL8 CXCL1 CSF3
23 11.51 TLR4 IL6 CXCL8 CXCL1
24 11.4 TLR4 IL6 CXCL8 CSF3
25 11.4 TLR4 IL6 IL17A CXCL8 CXCL1 CCL3
26 11.34 IL6 CXCL8 CXCL1 CSF3 CCL3
27 11.27 IL6 IL22 IL17A
28 11.2 IL6 CXCL1 CSF3
29 10.98 IL6 CXCL8 CRP
30 10.88 IL6 IL22 IL17A CXCL8 CXCL1 CSF3
31 10.4 IL6 IL22 IL17A CXCL8 CXCL1 CSF3

GO Terms for Bacterial Pneumonia

Cellular components related to Bacterial Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 SFTPD SFTPB SCGB1A1 IL6 IL22 IL17A
2 extracellular space GO:0005615 9.5 SFTPD SFTPB SCGB1A1 IL6 IL22 IL17A

Biological processes related to Bacterial Pneumonia according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.81 TLR4 SFTPD ELANE DEFB4A
2 immune response GO:0006955 9.76 TLR4 IL6 IL17A DEFB4A CXCL8 CXCL1
3 defense response to Gram-positive bacterium GO:0050830 9.75 IL6 DEFB4A CRP
4 defense response to Gram-negative bacterium GO:0050829 9.73 TLR4 IL6 DEFB4A
5 neutrophil chemotaxis GO:0030593 9.72 CXCL8 CXCL1 CCL3
6 cellular response to interleukin-1 GO:0071347 9.71 IL17A CXCL8 CCL3
7 chemotaxis GO:0006935 9.71 DEFB4A CXCL8 CXCL1 CCL3
8 chemokine-mediated signaling pathway GO:0070098 9.65 CXCL8 CXCL1 CCL3
9 cellular response to lipopolysaccharide GO:0071222 9.65 TLR4 IL6 CXCL8 CXCL1 CSF3
10 response to glucocorticoid GO:0051384 9.63 SCGB1A1 IL6 IL22
11 positive regulation of chemokine production GO:0032722 9.61 TLR4 IL6
12 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.61 DEFB4A CXCL8 CXCL1
13 embryonic digestive tract development GO:0048566 9.6 CXCL8 ADA
14 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.59 TLR4 IL17A
15 positive regulation of calcium-mediated signaling GO:0050850 9.58 CCL3 ADA
16 macrophage chemotaxis GO:0048246 9.57 SFTPD CCL3
17 acute-phase response GO:0006953 9.54 IL6 IL22 CRP
18 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.52 TLR4 ELANE
19 cytokine-mediated signaling pathway GO:0019221 9.5 IL6 IL22 IL17A CXCL8 CXCL1 CSF3
20 negative regulation of lipid storage GO:0010888 9.49 IL6 CRP
21 negative regulation of chemokine biosynthetic process GO:0045079 9.32 IL6 ELANE
22 inflammatory response GO:0006954 9.23 TLR4 IL6 IL22 IL17A CXCL8 CXCL1

Molecular functions related to Bacterial Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 IL6 IL22 IL17A CXCL8 CXCL1 CSF3
2 chemokine activity GO:0008009 9.13 CXCL8 CXCL1 CCL3

Sources for Bacterial Pneumonia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....